Sutro Biopharma, Inc
111 Oyster Point Blvd
South San Francisco
California
94080
United States
Tel: 650.881.6500
Website: http://www.sutrobio.com/
Email: general@sutrobio.com
About Sutro Biopharma, Inc
Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies.
Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro’s platform technology also enabled the spin out of Vaxcyte (Nasdaq: PCVX) and the creation of VAX-24, a 24-valent pneumococcal conjugate vaccine in clinical studies for the prevention of invasive pneumococcal disease. Sutro’s rational design and precise protein engineering has enabled six product candidates in the clinic.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.
The platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates. In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
Stock Symbol: STRO
Our Purpose Is Our Patients
174 articles about Sutro Biopharma, Inc
-
Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
4/27/2023
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO) today announced the Company’s President of Research & Chief Scientific Officer, Trevor Hallam, Ph.D., will be departing from his position effective May 31, 2023 and will immediately join the Company’s Scientific Advisory Board.
-
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023
4/18/2023
Sutro Biopharma, Inc. today announced expanded preclinical data for STRO-003, its ROR1 targeting ADC, presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held in Orlando, Florida from April 14-19, 2023.
-
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
3/30/2023
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 17, 2023
3/17/2023
Sutro Biopharma, Inc. announced that on March 1, 2023, the Compensation Committee of Sutro’s Board of Directors granted to Anne Borgman, M.D. 175,000 shares of Sutro Biopharma stock options and 150,000 restricted stock units of Sutro common stock in connection with her appointment as Sutro’s Chief Medical Officer and granted 10,000 RSUs of Sutro common stock to one other new employee.
-
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
2/28/2023
Sutro Biopharma, Inc. today announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023.
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 17, 2023
2/17/2023
Sutro Biopharma, Inc. announced that on February 15, 2023, the Compensation Committee of Sutro’s Board of Directors granted 90,000 shares of Sutro Biopharma stock options and 130,000 restricted stock units of Sutro common stock.
-
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
1/9/2023
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO) today announced results from a Phase 1 dose-expansion study of STRO-002 (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC and interim safety data from exploratory cohort C, a cohort of 15 patients with advanced ovarian cancer treated at the higher dose of luvelta, (5.2mg/kg), along with prophylactic pegfilgrastim.
-
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.
-
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
12/21/2022
Sutro Biopharma, Inc. today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002.
-
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
12/10/2022
Sutro Biopharma, Inc. announced that its research collaborators at Fred Hutchinson Cancer Research Center presented data from the Compassionate Use Program on anti-leukemic activity of STRO-002 in pediatric patients with relapsed/refractory CBFA2T3-GLIS2 acute myeloid leukemia, commonly known as RAM phenotype AML, in an oral presentation at the 64th ASH Annual Meeting and Exposition in New Orleans, LA.
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
11/23/2022
Sutro Biopharma, Inc. today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.
-
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership. -
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
11/8/2022
Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, reported its financial results for the quarter ended September 30, 2022, its recent business highlights, and a preview of select anticipated milestones.
-
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
11/3/2022
Sutro Biopharma, Inc. announced that data from the Company’s compassionate use program on anti-leukemic activity of STRO-002, a novel folate receptor-α targeting ADC, in infants and children with relapsed/refractory CBF2AT3-GLIS2 acute myeloid leukemia will be reviewed in an oral presentation at the 64th American Society of Hematology Annual Meeting and Exposition.
-
Sutro Biopharma to Participate in Upcoming November 2022 Investor Conferences
11/2/2022
Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.
-
Sutro Biopharma Announces Departure of Chief Medical Officer
10/24/2022
Sutro Biopharma, Inc. today announced that Chief Medical Officer, Arturo Molina, M.D., M.S., F.A.C.P. will be leaving the company to pursue other opportunities, effective November 4, 2022.
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 19, 2022
8/19/2022
Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced that on August 16, 2022, the Compensation Committee of Sutro’s Board of Directors granted 63,000 Restricted Stock Units of Sutro common stock to three new employees.
-
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
8/8/2022
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the quarter ended June 30, 2022, its recent business highlights, and a preview of anticipated select milestones.
-
Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
7/26/2022
Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), today announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United States and Canada, for the development of a novel cytokine derivative therapeutic for the treatment of cancer.
-
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
7/12/2022
Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will host a virtual research forum in which it will unveil the next product candidate, discuss immunostimulatory ADCs (iADCs) as a novel modality, and highlight recent enhancement to its cell-free manufacturing platform.